Valeant Pharmaceuticals International Inc (VRX)
What is Valeant Pharmaceuticals International Inc.?
Valeant Pharmaceuticals International (VRX) is a multinational specialty pharmaceutical and medical device company who develop, manufacture and market a variety of products for the medical industry. Their medical products and branded pharmaceuticals are successfully used by customers from over 100 countries worldwide.
Valeant produces and markets a wide range of medical products and branded generic pharmaceuticals that are successfully used by customers from over 100 countries worldwide. Besides its core business, Valeant concentrates on developing new treatments and innovative R&D solutions.
Where do Valeant Pharmaceuticals work?
Valeant is headquartered in Laval, Quebec, Canada. The company has offices spanning the USA, South American, Central America, Asia Pacific and Europe. Valeant employs approximately 22,000 people who work across these locations, which include a number of manufacturing facilities and commercial bases.
In which areas does Valeant Pharmaceuticals operate?
Valeant operates a ‘different focus in different markets’ approach to their product management.
For the US market, the main focus is on eye care, aesthetics, dermatology, neurology, dentistry, gastrointestinal health, neurology and consumer products.
The Canada market targets pain management, cardiovascular disease, neurology, and dermatology. Valeant’s R&D Centre of Excellence is based at their Canadian headquarters in Laval, ensure quality of service.
Asia Pacific and Africa look towards the development of Over-the-Counter (OTC) medicines, medical devices and also prescription based products. These are marketed to many of the regions countries including Japan, China, South Korea and South Africa.
The Latin American segment takes at OTC products, prescriptions, generic medicines, including antibiotics and dermatology products, and other medical items with bases in Mexico, the Caribbean and Brazil.
Valeant’s European and Middle East market focuses on the development and marketing of branded generics, OTC products and other medical devices.
In Central and Eastern Europe, the company seeks to target and develop its OTC and generics medicines. Interesting, due to nostalgic reason among health professionals, many products in this area continue to be sold under past Valeant Europe brand names.
EMENA is a section of Valeant that encompasses the regions of Europe, Middle East and North Africa, targeting more than 35 countries in total. Their main markets include branded generics, OTC medicines and other pharmaceutical products.
Who are Valeant Pharmaceuticals’ main competitors?
The company faces tough competition in the pharma product arena. Their main competitors include Copenhagen firm Lundbeck and Abbott Laboratories, based in the US.
How is the financial outlook for Valeant Pharmaceuticals?
From 2014–2016, Valeant’s full-year revenue has averaged around $9.44 billion, made up of a 2016 full-year revenue of $9.67 billion, 2015 of $10.4 billion and 2014 of $8.25 billion, indicating continued financial stability for the company.
Where is Valeant Pharmaceuticals traded?
Valeant Pharmaceuticals is traded on the New York Stock Exchange (NYSE) and is included to the S&P/TSX 60 component. Find out more about the Valeant Pharmaceuticals share price at Capital.com